The use of adrenaline in extradural solutions has produced inconsistent effects on transplacental distribution of bupivacaine [1] [2] [3] [4] . The net transfer of bupivacaine is known to depend on concentration gradient, pH gradient, binding protein gradient and umbilical flow [5] . Adrenaline may indirectly influence placental transfer of bupivacaine by its effect on placental and uterine blood flow [6] [7] [8] .
It has been claimed that the low fetal: maternal (F: M) plasma concentration ratios of bupivacaine measured consistently at delivery following extradural analgesia are the result of extensive tissue uptake rather than slow placental transfer [9] . If this were so, the umbilical artery: maternal vein ratios should increase with time and bupivacaine would become progressively more toxic in the fetus during continuous extradural administration.
We have therefore studied maternal venous, umbilical venous and umbilical arterial bupivacaine concentrations at delivery in women undergoing Caesarean section under extradural blockade: both elective and emergency, after extradural analgesia in labour. We have also reexamined the effect of adrenaline on placental transfer of bupivacaine.
PATIENTS AND METHODS
Following Ethics Committee approval and informed consent, we studied 40 women undergoing elective and 40 women undergoing emergency Caesarean section under extradural blockade. This study was part of a wider project in which extradural technique, maternal effects and maternal plasma bupivacaine concentrations have been reported previously [10, 11] . All patients received 0.5 °o bupivacaine in an initial single fractionated 20-ml extradural dose, plus further doses if indicated clinically. Within the elective and emergency groups, patients randomly received either bupivacaine plain solution or bupivacaine with adrenaline 1 in 200000. The elective group had received no previous extradural analgesia, whereas in the emergency group all had received previously extradural plain bupivacaine during labour.
At delivery of the infant, a length of umbilical cord was isolated between clamps and samples of umbilical venous (UV) and umbilical arterial (UA) blood were obtained. Maternal venous blood (MV) was sampled also at delivery. Plasma bupivacaine concentrations were measured by a modification of the method of Reynolds and Beckett [12] with the ethyl homologue of bupivacaine as internal standard. Plasma and standard were alkalinized and extracted into ether, back extracted into hydrochloric acid and re-extracted into ether, which was concentrated by boiling, to approximately 10 ul. A 3-ul sample was analysed by gas chromatography using 3°o OV17 on AW Chromasorb WHP at the stationary phase, and a nitrogen detector.
Data were analysed using the SAS statistical package on the Amdahl V8 computer at the University of London Computer Centre. Differences between groups were tested by analysis of variance and Student's t test. The relationship of bupivacaine concentration and concentration ratios with time intervals was examined with Pearson and Spearman rank correlation. Results with P < 0.05 were considered significant.
RESULTS
Maternal age, weight and infant weight were not significantly different between the elective groups given plain or adrenaline solutions or the emergency groups given plain or adrenaline solutions (table I) .
The modal dose of bupivacaine for Caesarean section in all four groups was 100 mg. The dose of bupivacaine for labour analgesia before emergency Caesarean section was 121 (80) mg (mean (SD)) in the plain group and 113 (70) mg in the adrenaline group. Further details of these doses and the time course of maternal plasma concentrations of bupivacaine have been reported separately [11] . Plasma concentrations of bupivacaine (MV, UV and UA) were significantly greater (P < 0.0001) in the emergency groups than in the elective groups (table II) . Adrenaline was not associated with significant changes in plasma concentrations of local anaesthetic in MV, UV or UA.
Plasma concentrations of bupivacaine in MV increased significantly with the total dose (mg kg" 1 ) administered in the plain, adrenaline, elective (P < 0.0001) and emergency groups (P < 0.03).
The effect of time on maternal and fetal plasma concentrations of bupivacaine was investigated also. There were significant positive correlations for first dose to delivery interval (FDD) with MV, UV and UA, reflecting total dose (table III) . In contrast, there were mostly negative correlations for last dose to delivery interval (LDD) with MV and UV and no significant correlation with UA (table IV) .
Bupivacaine concentration ratios were greater in the emergency group compared with the elective group, but this difference was significant (P < 0.04) only for the UV:MV ratio. Adrenaline had no significant effect on UV: MV or UA: MV but in the elective group was associated with greater UA:UV ratios (P < 0.01) (table V).
In eight cases (table VI), the UA:UV ratio was substantially greater than 1. All of these mothers had received extradural adrenaline, and delivery occurred within 40-52 min of the last dose ( fig. 1) . There was no significant correlation between any ratios (UV:MV, UA:MV, UA:UV) and duration of extradural blockade as measured by FDD. In contrast, there were significant correlations between some of the ratios and LDD. The UA:UV ratio correlated significantly with LDD in the emergency group (r = 0.455; P < 0.01) and both adrenaline sub-groups.
The UV:MV ratio showed a negative correlation with LDD in all groups but was significant only in the elective plain group (r = -0.504; P < 0.03). For UA:MV and LDD, there was no overall correlation, although there was a negative correlation in the elective plain group (r = -0.561; P < 0.02) and a positive correlation in the emergency adrenaline group (r = 0.593; P < 0.02).
DISCUSSION
In this study, plasma concentrations of bupivacaine in MV increased significantly with the total dose of drug (mg kg" 1 ) administered. This is consistent with previous findings [2, 11] that maternal maximum concentration correlates with total dose but not with dose rate, and reflects the fact that, with continuous administration at a constant rate, plasma concentration of a drug increases for four to seven half-lives and only the plateau concentration reflects dose rate. As the elimination half-life of bupivacaine in parturients is 6h [13] to 9h [14, 15] , plasma concentrations are unlikely to plateau during the course of an obstetric extradural block. Transplacental distribution of bupivacaine has been investigated in animals [16] [17] [18] [19] by methods that are not applicable to humans. Simultaneous sampling of fetal and maternal blood at delivery is relatively simple in humans, but examines only one moment in a continuous process. We have attempted to overcome this problem by using subjects who received bupivacaine for varying periods of time.
Simultaneous concentrations of bupivacaine in UV, UA and MV have rarely been reported [20] . UV:MV ratios on initial administration are an index of placental transfer rate, and while fetal tissue saturation is incomplete, UA:MV bupivacaine concentration ratio should increase with time to reach a plateau which approaches the UV:MV ratio, although during maternal drug absorption a small gradient may persist if there is fetal drug metabolism. However, both UV:MV and UA:MV ratios are affected by transplacental pH gradient [21, 22] and are governed principally by the gradient of a,-acid glycoprotein [23, 24] . This major cause of interindividual variation should be overcome by examining UA: UV ratios, which gauge the extent of fetal equilibration and the direction of placental transfer but are independent of transplacental a,-acid glycoprotein gradient.
In this study, UA:UV increased significantly with LDD but not with FDD, which suggests that equilibration occurred during each dosage interval in approximately 30 min ( fig. 1 ). The negative relationship between UV:MV and time suggests that bupivacaine approached equilibrium across the placenta in a single circulation, while equilibration in the whole fetal compartment took less than 1 h, and in some cases reverse transfer occurred.
The eight UA: UV ratios markedly in excess of 1 ( fig. 1 , table VI) were unexpected. All occurred in patients receiving extradural adrenaline and within an LDD of 40-55 min. In five of these patients, relatively low maternal concentrations were clearly promoting reverse placental transfer. The phenomenon of back transfer has been reported previously [16] , although not in association with adrenaline. The infants at birth did not appear more acidotic than the others. Differences in fetal and maternal protein binding may play a role in this phenomenon, while maternal a,-acid glycoprotein concentration may increase during stress [25] .
UV: MV and UA: MV ratios were of the same order of magnitude and did not appear to approach unity with time. There is thus no evidence from the present study or recent animal work [17, 18] that high fetal tissue uptake of bupivacaine is the principal cause of low F:M ratios. Low equilibrium F:M ratios of bupivacaine may be explained by the reduced protein binding of bupivacaine in fetuses. This has been recorded consistently in man and rabbits [24, [26] [27] [28] and is related to the small concentrations of a,-acid glycoprotein in fetal blood [23, 24, 29] . The effect of pH on equilibrium F:M ratios has been well documented by others [21, 22] , and was not studied therefore in the present series.
As reported previously [1] , the use of extradural adrenaline was associated with higher F: M ratios, but this finding, although barely significant, would appear to be related more to UA: MV and UA:UV ratios than to UV:MV and was de-pendent upon the eight aberrant cases. Adrenaline was, therefore, not affecting placental transfer rate and in eight patients was associated with reverse transfer. This observation might in part reflect less fluctuation in maternal concentration, which would otherwise peak at or near delivery.
